{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T12:45:10Z","timestamp":1743425110911,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This study was funded by Bayer AG and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40262-022-01203-5","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:21:38Z","timestamp":1675358498000},"page":"321-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8931-4564","authenticated-orcid":false,"given":"Michael","family":"Boettcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0671-9644","authenticated-orcid":false,"given":"Bettina","family":"Nowotny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Krausche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-6726","authenticated-orcid":false,"given":"Corina","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"1203_CR1","unstructured":"US Food and Drug Administration. Verquvo\u2122 (vericiguat) tablets: highlights of prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214377s000lbl.pdf. Accessed 11 May 2022."},{"key":"1203_CR2","unstructured":"European Medicines Agency. Verquvo. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/verquvo. Accessed 16 January 2023."},{"issue":"36","key":"1203_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Aacute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"20","key":"1203_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"key":"1203_CR5","unstructured":"US Food and Drug Administration. Viagra\u00ae (sildenafil citrate) tablets: highlights of prescribing information. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/20895s039s042lbl.pdf. Accessed 7 Sept 2021."},{"key":"1203_CR6","unstructured":"European Medicines Agency. Viagra summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/viagra#product-information-section. Accessed 7 Sept 2021."},{"issue":"11","key":"1203_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-020-00895-x","volume":"59","author":"M Boettcher","year":"2020","unstructured":"Boettcher M, Gerisch M, Lobmeyer M, Besche N, Thomas D, Gerrits M, et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies. Clin Pharmacokinet. 2020;59(11):1407\u201318.","journal-title":"Clin Pharmacokinet"},{"key":"1203_CR8","unstructured":"US Food and Drug Administration. Vericiguat (Verquvo) integrated review: Center for Drug Evaluation and Research. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214377Orig1s000IntegratedR.pdf. Accessed 12 Apr 2021."},{"key":"1203_CR9","unstructured":"US Food and Drug Administration Department of Health and Human Services. Guidance for industry: bioanalytical method\nvalidation. 2001. https:\/\/www.moh.gov.bw\/Publications\/drug_regulation\/Bioanalytical%20Method%20Validation%20FDA%202001.pdf. Accessed 16 January 2023."},{"issue":"77","key":"1203_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","volume":"2021","author":"M Boettcher","year":"2021","unstructured":"Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;2021(77):527\u201337.","journal-title":"Eur J Clin Pharmacol"},{"key":"1203_CR11","doi-asserted-by":"crossref","unstructured":"Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, et al. Soluble GC stimulators and activators: past, present and future. Br J Pharmacol. 2021 (Online ahead of print).","DOI":"10.1111\/bph.15698"},{"issue":"6","key":"1203_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/pharmaceutics13060876","volume":"13","author":"M Murtadha","year":"2021","unstructured":"Murtadha M, Raslan MA, Fahmy SF, Sabri NA. Changes in the pharmacokinetics and pharmacodynamics of sildenafil in cigarette and cannabis smokers. Pharmaceutics. 2021;13(6):876.","journal-title":"Pharmaceutics"},{"key":"1203_CR13","unstructured":"European Medicines Agency. Adempas summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adempas-epar-product-information_en.pdf. Accessed 14 Sept 2021."},{"issue":"4","key":"1203_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903\u201375.","journal-title":"Eur Respir J"},{"issue":"5","key":"1203_CR15","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1183\/09031936.00105914","volume":"45","author":"N Galie","year":"2015","unstructured":"Galie N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314\u201322.","journal-title":"Eur Respir J"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01203-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T14:05:28Z","timestamp":1695737128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01203-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01203-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"12 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to include the electronic supplementary material.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Bayer AG and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Corina Becker and Bettina Nowotny are employees of Bayer AG. Michael-Friedrich Boettcher is a former employee of Bayer AG and has received within the last 36 months, salary, pension, and payment for writing and reviewing vericiguat manuscripts from Bayer AG and for lectures, exercises, and awarding and supporting bachelor and master theses. Robert Krausche is an employee of Chrestos Concept GmbH & Co. KG and was paid by Bayer AG to perform the statistical analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonisation guideline E6: Good Clinical Practice and met all local legal and regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before any study procedure was performed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Availability of the data underlying this publication will be determined according to Bayer\u2019s commitment to the EFPIA\/PhRMA \u201cPrinciples for responsible clinical trial data sharing\u201d. This pertains to scope, timepoint, and process of data access. As such, Bayer commits to sharing upon request from qualified scientific and medical researchers subject-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in volunteers for medicines and indications approved in the USA and European Union as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the European Union and US regulatory agencies on or after 1 January, 2014. Interested researchers can use  to request access to anonymized subject-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsors section of the portal. Data access will be granted to anonymized subject-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that volunteer privacy is safeguarded.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conception, design, or planning of the study. MB, BN, and CB contributed to the acquisition of the data. RK performed the data analysis and all authors contributed to the interpretation of the data. All authors contributed to writing the manuscript, commented on previous versions of the manuscript, and read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}